NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo

References

• KataokaKKwonGSYokoyamaMOkanoTSakuraiYBlock copolymer micelles as vehicles for drug deliveryJ Control Release1993241–3119132
   Web of Science ®Google Scholar
• KwonGSKataokaKBlock copolymer micelles as long-circulating drug vehiclesAdv Drug Deliv Rev1995162–3295309
   Web of Science ®Google Scholar
• KataokaKHaradaANagasakiYBlock copolymer micelles for drug delivery: design, characterization and biological significanceAdv Drug Deliv Rev200147111313111251249
   PubMed Web of Science ®Google Scholar
• MatsumuraYMaedaHA new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancsCancer Res19864612 Pt 1638763922946403
   PubMed Web of Science ®Google Scholar
• VeroneseFMSchiavonOPasutGPEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activityBioconjug Chem200516477578416029018
   PubMed Web of Science ®Google Scholar
• HaradaMBobeISaitoHImproved anti-tumor activity of stabilized anthracycline polymeric micelle formulation, NC-6300Cancer Sci2011102119219921040218
   PubMed Web of Science ®Google Scholar
• SwainSMJeongJHGeyerCEJrLonger therapy, iatrogenic amenorrhea, and survival in early breast cancerN Engl J Med2010362222053206520519679
   PubMed Web of Science ®Google Scholar
• NaitoSTsukamotoTKogaHDocetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in JapanJpn J Clin Oncol200838536537218417502
   PubMed Web of Science ®Google Scholar
• PosnerMRHershockDMBlajmanCRCisplatin and fluorouracil alone or with docetaxel in head and neck cancerN Engl J Med2007357171705171517960013
   PubMed Web of Science ®Google Scholar
• OzdemirNYAbaliHOksüzoğuBThe efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinomaMed Oncol201027368068419633962
   PubMed Web of Science ®Google Scholar
• DorrRTPharmacology of the taxanesPharmacotherapy1997175 Pt 296S104S9322876
   PubMed Web of Science ®Google Scholar
• KatsumataNNodaKNozawaSPhase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese cooperative studyBr J Cancer2005939999100416234823
   PubMed Web of Science ®Google Scholar
• OkadaSSakataYMatsunoSPhase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative studyBr J Cancer1999803–443844310408850
   PubMed Web of Science ®Google Scholar
• YokoyamaMMiyauchiMYamadaNPolymer micelles as novel drug carrier: Adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymerJ Control Release1990111–3269278
   Web of Science ®Google Scholar
• HaradaMSaitoHKatoYNanoCarrier Co, LtdDocetaxel polymer derivative, method for producing same and use of same PCT patent application WO 2009/142326 A12009
   Google Scholar
• JacksonJKGleaveMEYagoVBeraldiEHunterWLBurtHMThe suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxelCancer Res200060154146415110945622
   PubMed Web of Science ®Google Scholar
• ChipmanSDOldhamFBPezzoniGSingerJWBiological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugateInt J Nanomedicine20061437538317722272
   PubMed Web of Science ®Google Scholar
• ClarkeSJRivoryLPClinical pharmacokinetics of docetaxelClin Pharmacokinet19993629911410092957
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis [homepage on the Internet] Available from: http://di.sanofi-aventis.co.jp/interview/taxotere.pdf
   Google Scholar
• PlummerRWilsonRHCalvertHA phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumoursBr J Cancer2011104459359821285987
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration (FDA)Oncology tools: dose calculator [online tool]Silver Spring, MDFDA Available from: http://www.accessdata.fda.gov/scripts/cder/onctools/animalquery.cfm
   Google Scholar
• FujiharaTSawadaTHirakawaKEstablishment of lymph node metastatic model for human gastric cancer in nude mice and analysis of factors associated with metastasisClin Exp Metastasis19981643893989626818
   PubMed Web of Science ®Google Scholar
• HillBTWhelanRDShellardSAMcCleanSHoskingLKDifferential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitroInvest New Drugs19941231691827896535
   PubMed Web of Science ®Google Scholar
• LavelleFBisseryMCCombeauCRiouJFVrignaudPAndréSPreclinical evaluation of docetaxel (Taxotere)Semin Oncol1995222 Suppl 4316
   Web of Science ®Google Scholar
• LokichJAndersonNDose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agentsAnn Oncol19978115259093703
   PubMed Web of Science ®Google Scholar
• Bradshaw-PierceELEckhardtSGGustafsonDLA physiologically based pharmacokinetic model of docetaxel disposition: from mouse to manClin Cancer Res20071392768277617473210
   PubMed Web of Science ®Google Scholar
• HamaguchiTKatoKYasuiHA phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulationBr J Cancer200797217017617595665
   PubMed Web of Science ®Google Scholar
• HippoYYashiroMIshiiMDifferential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodesCancer Res200161388989511221876
   PubMed Web of Science ®Google Scholar
• YashiroMHirakawaKCancer-stromal interactions in scirrhous gastric carcinomaCancer Microenviron20103112713521209779
   PubMedGoogle Scholar
• NishiyamaMWadaSDocetaxel: its role in current and future treatments for advanced gastric cancerGastric Cancer200912313214119890692
   PubMed Web of Science ®Google Scholar
• BrunoRHilleDRivaAPopulation pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancerJ Clin Oncol19981611871969440742
   PubMed Web of Science ®Google Scholar
• GianniLKearnsCMGianiANonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humansJ Clin Oncol19951311801907799018
   PubMed Web of Science ®Google Scholar
• KanoMRBaeYIwataCImprovement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-beta signalingProc Natl Acad Sci U S A200710493460346517307870
   PubMed Web of Science ®Google Scholar
• ChabottauxVSounniNEPenningtonCJMembrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastasesCancer Res200666105165517216707440
   PubMed Web of Science ®Google Scholar
• HervéM-AButeau-LozanoHVassyROverexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vesselsAm J Pathol2008172116717818079435
   PubMed Web of Science ®Google Scholar
• LiuJZahediPZengFAllenCNano-sized assemblies of a PEG-docetaxel conjugate as a formulation strategy for docetaxelJ Pharm Sci20089783274329018064681
   PubMed Web of Science ®Google Scholar
• EsmaeiliFDinarvandRGhahremaniMHDocetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studiesJ Pharm Sci20099882718273018972321
   PubMed Web of Science ®Google Scholar
• MikhailASAllenCPoly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphologyBiomacromolecules20101151273128020369884
   PubMed Web of Science ®Google Scholar
• Nektar Therapeutics [homepage on the Internet] Available from: http://www.nektar.com/product_pipeline/oncology_nktr-105.htmlaccessed July 21, 2010
   Google Scholar